Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET.
馬薩諸塞州劍橋，2024年11月22日（環球資訊網）—— Seres therapeutics公司（納斯達克：MCRB），一家領先的現場生物治療公司，今天宣佈首席執行官埃裏克·沙夫將於2024年12月3日下午4:30參加派傑投資第36屆年度醫療健康大會的爐邊談話。
A live webcast of the chat will be accessible through the "Events and Presentations" tab on the "Investors and News" section of the Company's website at and will be available for replay following the event.
此次聊天的直播網絡廣播將通過公司網站「投資者與資訊」部分的「活動與演示」標籤訪問，並將在活動結束後提供重播。
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome therapeutic, and which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit .
投資者和媒體聯繫人：IR@serestherapeutics.com，卡羅·坦齊博士，肯達爾投資者關係公司，ctanzi@kendallir.com，Seres Therapeutics，Inc。
Seres therapeutics公司（納斯達克：MCRB）是一家臨床階段公司，專注於通過新型現場生物療法改善醫療脆弱人群的患者結果。Seres成功開發並獲批VOWSt，這是第一個獲得FDA批准的口服微生物組治療，並於2024年9月出售給奈斯特健康科學公司。該公司正在開發SER-155，該藥在接受異體造血幹細胞移植（allo-HSCT）的患者的臨床研究中，顯示出顯著減少血流感染及相關併發症（與安慰劑相比）。SER-155及該公司的其他管線項目旨在針對多種疾病相關途徑，並通過培養標準克隆電芯庫進行生產，而不是使用VOWSt所用的供體來源生產過程。除了allo-HSCt，該公司還計劃在其他醫療脆弱人群中評估SER-155和其他培養的現場生物治療候選藥物，包括自體-HSCt患者、具有中性粒細胞減少症的癌症患者、CAR-T接受者、慢性肝病患者、實臟器移植接受者以及重症監護室和長期急性護理設施中的患者。詳情請訪問 .
Investor and Media Contacts:
IR@serestherapeutics.com
投資者和媒體聯繫方式：IR@serestherapeutics.com，卡羅·坦齊博士，肯達爾投資者關係公司，ctanzi@kendallir.com，Seres Therapeutics，Inc。
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
肯達爾投資者關係公司
ctanzi@kendallir.com
ctanzi@kendallir.com
This press release was published by a CLEAR Verified individual.
此新聞發佈是由經過驗證的個人發佈的。
譯文內容由第三人軟體翻譯。
